Bacterial disease diagnostics market size to increase by USD 3,766.05 million between 2022 and 2027; Growth driven by high prevalence of infectious diseases - Technavio
NEW YORK, March 22, 2023 /PRNewswire/ -- The bacterial disease diagnostics market size is forecast to grow by USD 3,766.05 millionbetween 2022 and 2027. However, the growth momentum will be decelerating at a CAGR of 6.28% during the forecast period. The growth of the market is driven by factors such as the high prevalence of infectious diseases, the integration of digital health in rapid diagnostics for bacterial disease, and the growing number of merger and acquisition (M&A) activities.
The number of disease outbreaks has increased significantly over the past few years. Factors such as malnutrition, poor sanitation, poor water quality, and the lack of proper healthcare systems have increased the prevalence of infectious diseases. For instance, according to WHO, in 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. Similarly, the incidence of infectious diseases such as TB, malaria, and hepatitis is increasing worldwide. The rise in the incidence of various infectious diseases has increased the demand for bacterial disease diagnostics. All these factors are driving the growth of the market in focus. For more insights on the historic data (2017 to 2021) and forecast market size (2023 to 2027) ? Request a report sample
By region, the global bacterial disease diagnostics market is segmented into North America, Europe, Asia, and Rest of World (ROW). North America will account for 49% of market growth during the forecast period. The increase in the prevalence of bacterial diseases such as TB, meningitis, and pneumonia has been crucial in driving the growth of the regional market. The development of new antibacterial drugs and the increase in funding for the development of new therapies are other major factors supporting the growth of the bacterial disease diagnostics market in North America.
The global bacterial disease diagnostics market is fragmented due to the presence of several global and regional players. Key vendors are developing a comprehensive range of advanced bacterial disease diagnostics to strengthen their position and cater to the demands of end-users. Prominent vendors are trying to build a strong customer base by distributing the products through subsidiaries and other distribution channels worldwide. Besides, the market is witnessing collaborations and tie-ups of vendors with clinics and practitioners. All these factors will intensify the competition in the market during the forecast period.
The bacterial disease diagnostics market report includes information on the key products and recent developments of leading vendors, including:
Abbott Laboratories - The company offers bacterial disease diagnostics such as Abbott RealTime SARS-C0V-2 assay.
Accelerate Diagnostics Inc. - The company offers bacterial disease diagnostics such as Accelerate Pheno system.
Becton Dickinson and Co. - The company offers bacterial disease diagnostics such as BD Directigen immunoassay test kits.
Bio Rad Laboratories Inc. - The company offers bacterial disease diagnostics such as pGLO Bacterial Transformation Kit.
The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample
By product, the market is segmented into consumables and instruments.
By end-user, the market is segmented into hospitals and labs.
By geography, the market is segmented into North America, Europe, Asia, and Rest of World (ROW).
What are the key data covered in this bacterial disease diagnostics market report?
CAGR of the market during the forecast period.
Detailed information on factors that will drive the growth of the market between 2023 and 2027
Precise estimation of the size of the bacterial disease diagnostics market and its contribution to the parent market.
Accurate predictions about upcoming trends and changes in consumer behavior.
Growth of the market across North America, Europe, Asia, and Rest of World (ROW).
A thorough analysis of the market's competitive landscape and detailed information about vendors.
Comprehensive analysis of factors that will challenge the growth of bacterial disease diagnostics market vendors.
The hemostasis diagnostics market size is expected to increase by USD 1.12 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.95%. The market is segmented by end-user (hospitals and clinics, independent diagnostic centers, and research and academic institutions) and geography (North America, Europe, Asia, and the Rest of World (ROW)).
The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The market is segmented by product (SCIT and SLIT), type (allergic rhinitis, asthma, food allergy, and others), and geography (Europe, North America, Asia, and the Rest of World (ROW)).
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 49%
US, Canada, Germany, UK, and Japan
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Abbott Laboratories, Accelerate Diagnostics Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Bruker Corp., Danaher Corp., DiaSorin SpA, EKF Diagnostics Holdings Plc, F. Hoffmann La Roche Ltd., GENERI BIOTECH s.r.o., Great Basin Scientific, Hologic Inc., Meridian Bioscience Inc., Perkin Elmer Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens AG, T2 Biosystems Inc., and Takara Bio Inc.
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Exhibit 140: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 141: F. Hoffmann La Roche Ltd. - Key news
Exhibit 142: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 143: F. Hoffmann La Roche Ltd. - Segment focus
12.12 Hologic Inc.
Exhibit 144: Hologic Inc. - Overview
Exhibit 145: Hologic Inc. - Business segments
Exhibit 146: Hologic Inc. - Key news
Exhibit 147: Hologic Inc. - Key offerings
Exhibit 148: Hologic Inc. - Segment focus
12.13 Perkin Elmer Inc.
Exhibit 149: Perkin Elmer Inc. - Overview
Exhibit 150: Perkin Elmer Inc. - Business segments
Exhibit 151: Perkin Elmer Inc. - Key news
Exhibit 152: Perkin Elmer Inc. - Key offerings
Exhibit 153: Perkin Elmer Inc. - Segment focus
12.14 QIAGEN NV
Exhibit 154: QIAGEN NV - Overview
Exhibit 155: QIAGEN NV - Product / Service
Exhibit 156: QIAGEN NV - Key news
Exhibit 157: QIAGEN NV - Key offerings
12.15 Quest Diagnostics Inc.
Exhibit 158: Quest Diagnostics Inc. - Overview
Exhibit 159: Quest Diagnostics Inc. - Business segments
Exhibit 160: Quest Diagnostics Inc. - Key offerings
Exhibit 161: Quest Diagnostics Inc. - Segment focus
12.16 Siemens AG
Exhibit 162: Siemens AG - Overview
Exhibit 163: Siemens AG - Business segments
Exhibit 164: Siemens AG - Key news
Exhibit 165: Siemens AG - Key offerings
Exhibit 166: Siemens AG - Segment focus
12.17 Takara Bio Inc.
Exhibit 167: Takara Bio Inc. - Overview
Exhibit 168: Takara Bio Inc. - Business segments
Exhibit 169: Takara Bio Inc. - Key offerings
Exhibit 170: Takara Bio Inc. - Segment focus
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 171: Inclusions checklist
Exhibit 172: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 173: Currency conversion rates for US$
13.4 Research methodology
Exhibit 174: Research methodology
Exhibit 175: Validation techniques employed for market sizing
Exhibit 176: Information sources
13.5 List of abbreviations
Exhibit 177: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beyond Meat, Inc. ("Beyond Meat" or the "Company") and reminds investors of the July 10, 2023 deadline to seek the role of lead plaintiff in a...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cutera, Inc. ("Cutera" or the "Company") and reminds investors of the July 24, 2023 deadline to seek the role of lead plaintiff in a federal...
An initiative begun by Barrick president and chief executive Mark Bristow almost 13 years ago has come to fruition with the successful reintroduction of 16 white rhinos to the Garamba National Park in the northeast of the DRC, where the species was...
The chemical logistics market size is forecast to increase by USD 53.66 billion from 2023 to 2027, at a CAGR of 3.65%, according to the recent market study by Technavio. The growth of the chemical logistics market depends on several factors,...
True stories of successful Overseas Filipinos are making the rounds globally, in time for Independence Day in the Philippines.
Videos featuring Charmaine "Charm" Espinoza, a Filipina caregiver in the United Kingdom and Dan Johnson "DJ" Noblesa, a...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 10, 2023 to file lead plaintiff applications in a securities class action lawsuit against Beyond...